Section
This study uses single-cell RNA sequencing of bronchoalveolar lavage cells to reveal immune dysregulation in COPD, highlighting profibrotic macrophages and monocytes as key players in airway remodeling and gas exchange impairment.
This retrospective EBMT study identifies secondary autoimmune and inflammatory diseases as rare but significant complications following allo-HSCT, highlighting their incidence, risk factors, and impact on patient survival, calling for impro
Early results from the RESET-PV trial indicate that CD19 CAR T-cell therapy without lymphodepleting preconditioning is feasible and safe for pemphigus vulgaris, offering significant clinical improvement and durable B-cell depletion.
An interim analysis of the KONFIDENT-S open-label extension shows that oral sebetralstat is well tolerated and provides rapid symptom relief for breakthrough attacks in HAE patients on long-term prophylaxis.
This study elucidates distinct cellular expression patterns of IL-33 and its receptor variants ST2L and sST2 in COPD lungs, highlighting mast cells and endothelial cells as key mediators in the distal lung immune response.
IL-6 receptor blockade significantly reduces relapse rates in MOG antibody-associated disease, showing comparable efficacy to high-dose IVIG with a favorable safety profile, supporting its role in relapse prevention.
A novel adaptive Sino-Nasal Outcome Test (SNOT) yields improved correlation with computed tomography findings in chronic rhinosinusitis, enhancing clinical assessment and differentiation from allergic rhinitis.
Two immunologically distinct, age-independent subtypes of new-onset type 1 diabetes demonstrate differing progression rates and therapeutic responses, offering a path toward tailored immunotherapies.
This article reviews a retrospective study evaluating the feasibility and outcomes of a 24-week abrocitinib tapering regimen in moderate-to-severe atopic dermatitis, comparing dose reduction versus interval extension approaches and their im
This study evaluates the successful 24-week tapering of abrocitinib in moderate-to-severe atopic dermatitis patients, comparing dose reduction versus interval extension tapering regimens and demonstrating high feasibility with substantial d
EBV-positive diffuse large B-cell lymphoma exhibits severe systemic antiviral T-cell impairments and a suppressive tumor microenvironment driven by LMP1, revealing novel immunobiological insights with therapeutic implications.
Severe allergic transfusion reactions in group O recipients receiving group B or AB plasma or platelets are linked to IgE antibodies against the α-Gal epitope, highlighting a novel immunological mechanism and potential risk stratification a
A 2026 European Heart Journal study identifies macrophage circHIPK2 as a regulator of post-MI inflammation and fibrosis, with macrophage-targeted silencing improving cardiac remodeling in mice and showing translational promise in human myoc
Single-cell and spatial transcriptomics suggest that cardiac sarcoidosis evolves through region-specific inflammatory programs and intracardiac B-cell autoimmunity, with periplakin emerging as a candidate autoantigen.
New data identify GPR15L as an epithelial host-defense peptide that reshapes the colonic microbiota, reduces experimental colitis, and may have therapeutic relevance in inflammatory bowel disease.
In the phase 3A NIMBLE trial, switching biologic-responsive severe asthma patients to twice-yearly depemokimab preserved overall control and showed comparable safety, but formal noninferiority versus continued mepolizumab or benralizumab fo
This study used immune-cell gene expression and genetic analyses to identify causal genes and immune pathways linked to type 2 diabetes and its complications, highlighting diabetic neuropathy as a distinct cluster and prioritising ten promi
In a phase 2 randomized trial, oral vemircopan did not improve clinical outcomes over placebo in AChR-antibody–positive generalized myasthenia gravis, despite a mechanistically attractive strategy to selectively inhibit the alternative comp
Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c
A large-scale quality improvement study reveals that reclassifying penicillin allergies and providing pharmacy support can increase the use of intracameral cefuroxime from 2% to over 70%, significantly improving evidence-based prophylaxis i
